China’s NMPA granted clinical trial clearance to CSPC Pharmaceutical Group for JMT‑206, a weight‑management candidate for people with obesity or overweight and at least one weight‑related comorbidity. The approval allows CSPC to begin clinical development domestically and reflects accelerating competition in GLP‑1 and non‑GLP‑1 metabolic programs in China. CSPC said the clearance covers clinical development, manufacturing and commercialization activities in China.